lawsuits falter for investor specializing in legal disputes
In a significant development, Genflow Biosciences, a listed longevity business, has announced a series of new partnerships aimed at assessing the potential of gene therapy to extend the healthy lifespan of dogs and other pets. This promising research has sparked 'strong industry interest', potentially leading to licensing deals and commercialisation.
Genflow's focus on developing therapies that might extend the lives of dogs is gaining traction, with two major animal health companies showing interest and signing confidentiality agreements. The current centrepiece of their research is the gene therapy GF-1004, which is being tested in beagles through Genflow's GF-1004 dog ageing study. So far, no reported safety issues have arisen.
The gene therapy under development is based on a SIRT6 variant associated with people who live beyond 100 years. Genflow's team is working diligently to harness this discovery for the benefit of our furry friends.
In other news, Genflow Biosciences is set to streamline its operations following the acquisition of the remaining 50% of REINFO with no cash cost. This move is expected to further boost the company's growth trajectory.
Interestingly, for those considering investment opportunities, various DIY investing platforms are available, including AJ Bell, Hargreaves Lansdown, interactive investor, InvestEngine, and Trading 212. The shares of Genflow Biosciences ended the week up 18%, reflecting the positive sentiment in the market.
As Genflow Biosciences continues to push the boundaries of scientific research, it's an exciting time for both the longevity industry and pet owners alike. The potential for extending the healthy lifespan of dogs through gene therapy could open up a new era in pet care.
Read also:
- Shaping India's Economic Progression: Readying the Financial System for Tomorrow
- Conflict between Ben & Jerry's co-founder and Unilever over Gaza issues leads to resignation of co-founder
- Two farmers in Zambia take legal action against two firms with Chinese connections, alleging an ecological disaster caused by their operations.
- Deepening EU-India relations despite apprehensions regarding Moscow connections
